Near infrared II laser controlled free radical releasing nanogenerator for synergistic nitric oxide and alkyl radical therapy of breast cancer

Wei, Weiwei; Yang, Yan; Liang, Zhuoying; Song, Xi-Ling; Huang, Yadong; Qiu, Lin; Qiu, Xiaozhong; Yu, Shujuan; Wang, Xue

doi:10.1039/d1nr01859k

Cited by 32 publications

(17 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…N,N-bis(Carboxymethyl)-N,N-dinitroso-p-phenylenediamine (BNN6) is the most commonly used N-nitrosoamine. [158,159] Based on the second approach, Huang et al utilized magnesium silicate-coated upconverting nanoparticles UCNPs@MgSiO 3 based on a yolk-shell structure as a carrier to load the NO precursor BNN6 and anticancer drug DOX Figure 22. [160] UCNPs can convert NIR to UV or visible light, activating the loaded BNN6 to release NO, which avoids the phototoxicity of direct UV light excitation.…”

Section: Light-triggered Releasementioning

confidence: 99%

Controllable Nitric Oxide‐Delivering Platforms for Biomedical Applications

Liu

2022

Advanced Therapeutics

View full text Add to dashboard Cite

Nitric oxide (NO) serves a multitude of functions in human physiology and pathology, and therapeutic NO-releasing materials are vigorously developed for biomedical applications. Owing to its complex functions and its potential systemic effects, controllable NO release is desired for clinical applications. This review summarizes recent developments in the last five years in designing controllable NO-delivering platforms for treating diseases such as cancer, bacterial infection, cardiovascular diseases, wounds, and eye diseases, with a focus on the most commonly used NO donors, including N-diazeniumdiolates, S-nitrosothiols, arginine, and N-nitrosoamines. The progress and success of NO delivery strategies are highlighted, and their limitations are also included. Moreover, the therapeutic mechanisms of NO in the diseases are summarized, along with the corresponding means of controlling NO release. Finally, the prospects and potential challenges regarding the development of NO gas therapy are described, with the hope of encouraging new research in this area.

show abstract

Section: Light-triggered Releasementioning

confidence: 99%

Controllable Nitric Oxide‐Delivering Platforms for Biomedical Applications

Liu

2022

Advanced Therapeutics

View full text Add to dashboard Cite

show abstract

“…The synergistic action of NO and alkyl radicals induced the high oxidative stress in mitochondria, which could not only accelerate the release of cytochrome C to cause mitochondrial membrane damage but also significantly down-regulate the Bcl-2 protein to trigger the apoptosis of tumor cells. Animal experiments have shown that mice treated with this strategy can survive for more than 40 days and have a tumor suppression rate of more than 70% (Figure 3C) [78]. Furthermore, Tian et al designed a type of microsphere for the treatment of cold tumors using the photothermal agent IR1061, NO donor SNO and 1-methyl-tryptophan(1-MT).…”

Section: Second Nir (Nir-ii) Photothermal Triggered No Nanomedicinesmentioning

confidence: 99%

Stimuli Responsive Nitric Oxide-Based Nanomedicine for Synergistic Therapy

et al. 2021

View full text Add to dashboard Cite

Gas therapy has received widespread attention from the medical community as an emerging and promising therapeutic approach to cancer treatment. Among all gas molecules, nitric oxide (NO) was the first one to be applied in the biomedical field for its intriguing properties and unique anti-tumor mechanisms which have become a research hotspot in recent years. Despite the great progress of NO in cancer therapy, the non-specific distribution of NO in vivo and its side effects on normal tissue at high concentrations have impaired its clinical application. Therefore, it is important to develop facile NO-based nanomedicines to achieve the on-demand release of NO in tumor tissue while avoiding the leakage of NO in normal tissue, which could enhance therapeutic efficacy and reduce side effects at the same time. In recent years, numerous studies have reported the design and development of NO-based nanomedicines which were triggered by exogenous stimulus (light, ultrasound, X-ray) or tumor endogenous signals (glutathione, weak acid, glucose). In this review, we summarized the design principles and release behaviors of NO-based nanomedicines upon various stimuli and their applications in synergistic cancer therapy. We also discuss the anti-tumor mechanisms of NO-based nanomedicines in vivo for enhanced cancer therapy. Moreover, we discuss the existing challenges and further perspectives in this field in the aim of furthering its development.

show abstract

“…As a typical free radical initiator, 2,2′-azobis[2-(2-imidazolin-2-yl)propane]-dihydrochloride (AIPH) can generate alkyl radicals at high temperatures. 12 It does so even in the absence of oxygen. The generated free radicals are toxic to cells and will immediately oxidize cell elements or interact with oxygen to produce secondary toxic substances.…”

Section: Introductionmentioning

confidence: 99%

“…The released alkyl radicals can induce apoptosis of cancer cells by increasing oxidative stress, leading to cellular lipid and DNA damage. As a typical free radical initiator, 2,2'-azobis[2-(2-imidazolin-2-yl) propane]-dihydrochloride (AIPH) can generate alkyl radicals at high temperatures 12 . It does so even in the absence of oxygen.…”

Section: Introductionmentioning

confidence: 99%